2 models fit Gyre Therapeutics Inc. Common Stock and they agree: 2 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)
Valued as a growth company: Discounted cash flow and EV/EBITDA comparison.
ACCE opinionGyre Therapeutics Inc. Common Stock (GYRE)
Fair value (2 models)
$1.61
ACCE price target
$5.40
Rating
Overvalued
Horizon
12 months
Fair value published on 24 Oct 2026, 17:04 CEST; previously $2.00 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 14 Oct 2026, 00:00 CEST.
Rating published on 24 Oct 2026, 17:04 CEST.
Price used: $5.85 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
263.3% above
-72.5% to fair value
ACCE score
31
out of 100
Analysts
100% buy
3 covering
P/E
0.0x
forward 97.5x
1-year return
-28.9%
Dividend yield
0.00%
Gyre Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Gyre Therapeutics sells Envarsus XR, an extended-release tacrolimus tablet used to prevent organ rejection in transplant patients, and its margin profile reflects a product business with a 93.8% gross margin. The thesis rests on that product franchise and whether it can carry the company through a period of shrinking revenue. Revenue is declining 2.1% year over year, and operating margin sits at -47.6%, so the business is currently spending well beyond what it earns. The stock trades at a forward P/E of 188.7 against an ROE of -17.4%, which leaves little valuation support unless the revenue line stabilises. The name has a score of 32 out of 100 and no index membership, which fits a company where the question is still whether the franchise can return to growth, and that is the first thing to check before going further.